Peter G Shields
Ohio State University Comprehensive Cancer Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Peter G Shields as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 01:02 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT06038526 · Evaluation of Canakinumab in High-Risk Former-SmokersPeter Shields · completed · Cigarette Smoking-Related Carcinoma, Lung Carcinoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 01:02 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 16 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- The Ohio State University Tobacco Center of Regulatory Science (OSU-TCORS)U54CA287392 · NCI · OHIO STATE UNIVERSITY · fiscal years 2023 to 2026 · $3,856,991 awarded in 2026Same name and institution; not confirmed by an ID
- Training Program for Cancer Prevention and ControlT32CA229114 · NCI · OHIO STATE UNIVERSITY · fiscal years 2018 to 2026 · $371,619 awarded in 2026Same name and institution; not confirmed by an ID
- The Effects of a Standardized Research E-Cigarette On The Human Lung: A Clinical Trial With Bronchoscopic BiomarkersU01DA045530 · NIDA · OHIO STATE UNIVERSITY · fiscal years 2017 to 2018 · $724,169 awarded in 2018Same name and institution; not confirmed by an ID
- Project 2: Understanding Adolescent Trajectories, Exposures and Suscep P50CA180908 · NCI · OHIO STATE UNIVERSITY · fiscal years 2013 to 2017 · $551,343 awarded in 2017Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 01:02 UTC. The ranking covers the 200 most relevant of 26 PubMed records, and a shared surname and initials can bring in a namesake. All 26 on PubMed
- Circulating tumor cells: a useful predictor of treatment efficacy in metastatic breast cancer.J Clin Oncol · 2009253 citationsRCR 5.3
- Nicotine metabolite ratio predicts efficacy of transdermal nicotine for smoking cessation.Clin Pharmacol Ther · 2006227 citationsRCR 6.8
- Reduced nicotine content cigarettes: effects on toxicant exposure, dependence and cessation.Addiction · 2010208 citationsRCR 7.6
- The functional mu opioid receptor (OPRM1) Asn40Asp variant predicts short-term response to nicotine replacement therapy in a clinical trial.Pharmacogenomics J · 2004144 citationsRCR 4.3
- Toward personalized therapy for smoking cessation: a randomized placebo-controlled trial of bupropion.Clin Pharmacol Ther · 2008144 citationsRCR 4.3
- Pharmacogenetic investigation of smoking cessation treatment.Pharmacogenetics · 2002142 citationsRCR 4.1
- Effects of dopamine transporter and receptor polymorphisms on smoking cessation in a bupropion clinical trial.Health Psychol · 2003118 citationsRCR 3.2
- Relation between food reinforcement and dopamine genotypes and its effect on food intake in smokers.Am J Clin Nutr · 200477 citationsRCR 2.2
- Pharmacogenetic clinical trial of sustained-release bupropion for smoking cessation.Nicotine Tob Res · 200772 citationsRCR 2.2
- Effects of Electronic Cigarette Constituents on the Human Lung: A Pilot Clinical Trial.Cancer Prev Res (Phila) · 202070 citationsRCR 4.6